News

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has granted a 2018 Therapeutic Pipeline Award to Progenra to support the company’s development of small molecule treatment candidates for Parkinson’s disease. “Progenra is pleased to have been selected by The Michael J. Fox Foundation to contribute…

Parkinson’s disease patients voluntarily controlled brainwaves associated with motor symptoms using a neurofeedback system, according to new research. These findings have implications for how to best harness brain activity and deep brain stimulation to treat Parkinson’s disease symptoms. The study, “Real-time neurofeedback to modulate…

Parkinson’s disease can sometimes mask the symptoms of other neurological disorders, according to a case report. The report, titled “NMDAR encephalitis presenting as akinesia in a patient with Parkinson disease,” documents the case of a 71-year-old woman who was eventually diagnosed with encephalitis, the symptoms…

Blocking a key enzyme responsible for the production of a type of fat can become a potential therapeutic approach to treat Parkinson’s disease, Yumanity Therapeutics recently announced. The company revealed that inhibiting an enzyme…

Supplements of omega-3 fatty acids and vitamin E may help control genes involved in brain inflammation and body metabolism in patients with Parkinson’s disease, a study has found. The study, “The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression related to inflammation, insulin…

Nicotine may protect the brain from manganese and iron metal trace elements thought to be involved in the onset of Parkinson’s disease, a study based on a disease cell model reported. The study, “Nicotine protects against manganese and iron-induced toxicity in SH-SY5Y cells: Implication for Parkinson’s disease,” was published…

Parkinson’s patients show less ability to participate in work life even in the early stages before they are diagnosed with the disease, a study shows. In combination with biochemical and genetic biomarkers, this finding may help identify patients at risk of developing this progressive neurodegenerative disease before motor…

A new initiative by Acorda Therapeutics uses art to help people with Parkinson’s disease recognize and communicate about their off-period experiences. The initiative, called Framing OFF Through Art, builds on Acorda’s Live Well. Do Tell program, launched earlier this year. Framing OFF Through Art includes artwork inspired by the…

Rodin Therapeutics has started a Phase 1 clinical trial to explore the safety of its synthetic compound, RDN-929, to treat neurodegenerative diseases, including Alzheimer’s and Parkinson’s, by protecting synapses. The trial (NCT03668314), is designed to assess the safety, tolerability, pharmacokinetics — how the body affects a medicine…

Two compounds found in coffee — caffeine and EHT, a fatty acid molecule derived from serotonin — work together to protect the brain from damage induced by alpha-synuclein, a study in mice reported. The study, “Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson’s disease and…